| id | Study | Lib. in paper | Exposition period | Study type  | 
                Control type  | 
                Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S9606 R34059  | 
                Burja (Carbamazepine) (Controls unexposed, disease free), 2006 | Withdrawal symptoms | during pregnancy (anytime or not specified) | retrospective cohort (registry) | unexposed, disease free excluded | Adjustment: No | 
                    11.38 [0.22;590.18] C  excluded (control group)  | 
                
                0/19 0/211 | 0 | 19 | 
                    
                    
                         | 
                ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9607 R34064  | 
                Burja (Carbamazepine) (Controls unexposed, sick), 2006 | Withdrawal symptoms | during pregnancy (anytime or not specified) | retrospective cohort (registry) | unexposed, sick | Adjustment: No | 1.70 [0.03;89.48] C | 0/19 0/32 | 0 | 19 | 
                    
                    
                         | 
                ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9614 R34146  | 
                Dean (Carbamazepine), 2002 | Neonatal withdrawal features | at least 1st trimester excluded | retrospective cohort | unexposed, sick | Adjustment: No | 
                    6.27 [0.77;51.03] C  excluded (exposition period)  | 
                
                10/69 1/38 | 11 | 69 | 
                    
                    
                         | 
                ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 1 studies | 1.70 [0.03;89.48] | 0 | 19 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1: Carbamazepine) (Controls unexposed, sick;
Funnel plot not drawn. Less than 3 points.
Asymetry test p-value = NaN (by Egger's regression)
not enought points
Funnel plot not drawn. Less than 3 points.
excluded 9606